Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Suvoda earns two PM360 Innovation Awards for Sofia AI assistant and Suvoda AppSuvoda wins two PM360 Innovation Awards for Sofia AI assistant for clinical trials, and the Suvoda App, easing burdens for sites, sponsors, and patients.
- Avacta Group PLC LONDON andAvacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 TrialAvacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces today that it has achieved clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate (PDC) platform in the ongoing phase 1 FOCUS-01 trial.
- MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical TrialMilestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies
- VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCsNew data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities
- Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia CarePARSIPPANY, N.J., and — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of LongActingImpact.com, a new educational website for healthcare providers (HCPs) with information to support informed treatment discussions and decision-making around the role of long-acting injectables (LAIs) in schizophrenia care. This bespoke resource is intended to equip clinicians with key information on LAI benefits and practical guidance for discussing LAIs with their patients.
- Novo and Anthropic will collaborate to advance drug discovery with ClaudeCompanies: Novo NordiskNovo and Anthropic collaboration will help Novo accelerate the development of new medicines and advance AI-driven software development
- Syneos Health and Tufts CSDD Study Shows Clinical Trial Performance Depends More on Operating Model Design Than Sourcing StrategyData From 13 Leading Pharmaceutical Companies Points to Execution, Governance and Partner Coordination as Key Drivers of Trial Performance
- Label-Free Array Systems Market Forecasts Growth from $1.59B (2026) to $2.1B by 2030, Profiling Cytiva, Sartorius, Bruker, Malvern Panalytical & 17 Other Key PlayersOpportunities center on real-time, high-throughput drug discovery and diagnostics, driven by SPR/BLI advances, AI analytics, CRO adoption, improved sensitivity and Asian localization.
- Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key PlayersThe global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and North America dominates the market. Key players include Abbott, Roche, Danaher and Siemens Healthineers.
- Nucleic Acid Isolation and Purification Market Forecasts Growth from $5.41B (2026) to $10.52B by 2035, Profiling Roche, Promega, Macherey-Nagel & 7 Other Key PlayersCompanies: Roche HoldingNGS, personalized medicine, RNA therapeutics and chronic disease testing are driving demand for automated, magnetic and microfluidic purification solutions.
- WuXi BiologicsWuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG LeadershipForbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China...
- MESSAGE DU CEO DE TME PHARMATME Pharma informe ses actionnaires des négociations finales pour NOX-A12, de sa rigueur financière, de la faible dilution et du marché biotech.